ALK and neuroblastoma: Palmer’s group showed that both FAM150A and FAM150B were not only able to bind and activate human wild type ALK, but also constitutively active ALK mutants from neuroblastoma, resulting in a further enhanced activity or ‘superactivation’ [28].